Indian Pharma Market growth slips to 5.1% in October 2019
The Indian Pharmaceutical Market (IPM) growth has slipped to 5.1 per cent for the month of October 2019 after an 11.9 per cent growth in September.
The drop in growth for the month of October 19 has been seen across all the therapies, anti-infective market showing a growth of 2.9 per cent, while cardiac market at 7.9 per cent, GI market at 4.7 per cent, the anti-diabetic market at 6.4 per cent and Vitamins showing a growth of 2.3 per cent.
According to AIOCD AWACS report, the IPM has recorded sales of Rs.137,490 crore and a growth of 9.2 per cent for Moving Annual Total (MAT) basis during October 2019.
Among the top 50 corporates, 27 corporates exhibited double digit growth. Among the top 50 corporates, 40 corporates exhibited positive growth for the month of October, 2019.
Amongst the top 10 corporates, Lupin exhibits the highest growth (9%) followed by Intas (8.4%) and Sun & Zydus (7%). Amongst the 11-20 ranked Corporates, Aristo exhibits highest growth (17.8%) followed by Pfizer (17.7%) and Dr Reddy’s (17.5%). Amongst the 21-30 ranked Corporates, Cadila exhibits highest growth (10.5%), followed by FDC (4.6%) and Indoco Remedies (3.3%).
Amongst the 31-40 ranked corporates, La Renon exhibits the highest growth (23.9%) followed by JB Chemicals (14.7%) and Meyer Organics (10.4%). Amongst the 41-50 ranked Corporates, Boehringer Ingelheim exhibits the highest growth (38.9%), followed by Fourrts (20.6) and Corona (17.3%).
Amongst the 51-60 ranked corporates, Fresenius Kabi exhibits the highest growth (30.7%) followed by Pharmed (13.8%).Amongst the 61-70 ranked Corporates, Danone exhibits the highest growth (22.2%), followed by Eli Lilly (21.8%) and Koye Pharma (19.3%).
Amongst the 71-80 ranked corporates, Leeford HC exhibits the highest growth (28.4%), followed by Oaknet HC (12.9%) and Integrace Health (12.2%). Amongst the 81 -90 ranked Corporates, Roche exhibits highest growth (18.8%), followed by Samarth (16%).
Amongst the 91 -100 ranked corporates, Unison exhibits the highest growth (11.5%), followed by Med Manor (7.3%).
Amongst the 101 -150 few of the corporates exhibiting double digit growths are Indiabulls Pharma, Celon Labs, Linux Labs, Elan, Juggat, Entod, MSN, Icpa Health, Menarini India, Dabur, Deys Medicals, Seagull, Gland, Johnson & Johnson, Innovcare, Galpha, Stadmed, Comed, Icon, Reckitt Benckiser.
Among the top 10 companies, Sun Pharma, Cipla, Lupin and Zydus and close to double digit growth while Mankind, Alkem and Torrent in the in line with IPM growth for the month and Intas, Glaxo and Abbott have slowed down for the month.
Amongst the top MNC’s, Boehringer Ingelheim (38.9%) exhibits the highest growth followed by Fresenius Kabi (30.7%), Eli Lilly (21.8%), Roche (18.8%), Pfizer (17.7%), Sanofi India (2.2%).
FDC related market showed negative growth of -61.2% while the Approved FDC market showed a growth of 5.1% while the single molecules growth as well took a dip to 5.7% for the month.
The approved FDC component growth drivers are volumes at (-3.7%), prices at 5.8%, while new introduction exhibits a high growth of 2.9%.
The single molecules growth drivers are volumes (-1.1%), price growth of 4.7% and new introductions at 2.2%.
The NLEM 2013 containing molecules market showed growth at 5.3 per cent whereas the non NLEM market grew at 5.1 % resulting in an overall growth of 5.1 % for the month of October’19.
Among the top brands, Mixtard has maintained the top position for the month of Oct’19. While Lantus has gained a position and moved to second position, while Glycomet-GP has slipped to third position.
Janumet has moved up to fourth position by replacing Galvus Met as fifth. Duphaston gained second position and climbed to eight position.
Few major brands who have dropped in ranks Phensedyl Cough Linctus (-3), Istamet (-6), Volini (-3), Zincovit (-4), Shelcal (-3).
From therapy (Super Group) perspective, 14 of the 20 therapies are reflecting a growth of average 5%. Highest among that being cardiac (7.9%), followed by hormones (6.5%), antidiabetic (6.4%) & neuro/CNS (6.1%)
Vitamins and minerals (2.3%), gynaecology (2.9%), anti-neoplastic (3.4%) & derma (3.6%) are showing lower growths, while urology, blood related and sex stimulants are showing 10% plus growth
From the regional perspective, 14 of the regions are above the IPM growth of 5.1% and 17 regions below the IPM.
As of MAT October, 19 patented and in-licenced brands contribute to 4.46% of IPM and contributes to 8.7% of the incremental gains in the IPM and growing at 17.9%.
Glimepiride+metformin market (Rs.2,390 crore), consolidated Rs.235 crore and reflecting a growth of 11% on MAT and 6.5% for the month. Amoxycillin+clavulanic acid market (Rs.2,201 crore) consolidated Rs.227 crore at a growth of 12%. Paracetamol market (Rs.1,129 crore) has consolidated Rs.163 crore and a growth of 17 per cent.
Itraconazole (Rs.935 crore) consolidated 107 crore with a growth of 13%. Montelukast+levocetirizine (Rs.812 crore) added 57% with a growth of 8%. The luliconazole market is worth Rs.434 crore is exhibiting a growth of 15 per cent.
Voglibose+metformin+glimepiride (Rs.796 crore) added 140 crore with a growth of 21%. Telmisartan (Rs.768 crore)growing at 18%, added Rs.116 crore. montelukast+levocetrizine (Rs.808 crore) is exhibiting growth of 12%
Domperidone+Esomeprazole and Domperidone+omeprazole that are growing at 21% and 13% respectively, pantoprazole at 9% and rabeprazole at 5 per cent. The vildagliptin market valued at Rs.997 crore has exhibited degrowth (-14%) for the month.
Gliptins market (3611 crore) continues to grow double digit in combinations, while monotherapy market stagnant/degrowing, sitagliptin (-0.32%), vildagliptin (1.78%), saxagliptin (-5%).
The drop in growth for the month of October 19 has been seen across all the therapies, anti-infective market showing a growth of 2.9 per cent, while cardiac market at 7.9 per cent, GI market at 4.7 per cent, the anti-diabetic market at 6.4 per cent and Vitamins showing a growth of 2.3 per cent.
According to AIOCD AWACS report, the IPM has recorded sales of Rs.137,490 crore and a growth of 9.2 per cent for Moving Annual Total (MAT) basis during October 2019.
Among the top 50 corporates, 27 corporates exhibited double digit growth. Among the top 50 corporates, 40 corporates exhibited positive growth for the month of October, 2019.
Amongst the top 10 corporates, Lupin exhibits the highest growth (9%) followed by Intas (8.4%) and Sun & Zydus (7%). Amongst the 11-20 ranked Corporates, Aristo exhibits highest growth (17.8%) followed by Pfizer (17.7%) and Dr Reddy’s (17.5%). Amongst the 21-30 ranked Corporates, Cadila exhibits highest growth (10.5%), followed by FDC (4.6%) and Indoco Remedies (3.3%).
Amongst the 31-40 ranked corporates, La Renon exhibits the highest growth (23.9%) followed by JB Chemicals (14.7%) and Meyer Organics (10.4%). Amongst the 41-50 ranked Corporates, Boehringer Ingelheim exhibits the highest growth (38.9%), followed by Fourrts (20.6) and Corona (17.3%).
Amongst the 51-60 ranked corporates, Fresenius Kabi exhibits the highest growth (30.7%) followed by Pharmed (13.8%).Amongst the 61-70 ranked Corporates, Danone exhibits the highest growth (22.2%), followed by Eli Lilly (21.8%) and Koye Pharma (19.3%).
Amongst the 71-80 ranked corporates, Leeford HC exhibits the highest growth (28.4%), followed by Oaknet HC (12.9%) and Integrace Health (12.2%). Amongst the 81 -90 ranked Corporates, Roche exhibits highest growth (18.8%), followed by Samarth (16%).
Amongst the 91 -100 ranked corporates, Unison exhibits the highest growth (11.5%), followed by Med Manor (7.3%).
Amongst the 101 -150 few of the corporates exhibiting double digit growths are Indiabulls Pharma, Celon Labs, Linux Labs, Elan, Juggat, Entod, MSN, Icpa Health, Menarini India, Dabur, Deys Medicals, Seagull, Gland, Johnson & Johnson, Innovcare, Galpha, Stadmed, Comed, Icon, Reckitt Benckiser.
Among the top 10 companies, Sun Pharma, Cipla, Lupin and Zydus and close to double digit growth while Mankind, Alkem and Torrent in the in line with IPM growth for the month and Intas, Glaxo and Abbott have slowed down for the month.
Amongst the top MNC’s, Boehringer Ingelheim (38.9%) exhibits the highest growth followed by Fresenius Kabi (30.7%), Eli Lilly (21.8%), Roche (18.8%), Pfizer (17.7%), Sanofi India (2.2%).
FDC related market showed negative growth of -61.2% while the Approved FDC market showed a growth of 5.1% while the single molecules growth as well took a dip to 5.7% for the month.
The approved FDC component growth drivers are volumes at (-3.7%), prices at 5.8%, while new introduction exhibits a high growth of 2.9%.
The single molecules growth drivers are volumes (-1.1%), price growth of 4.7% and new introductions at 2.2%.
The NLEM 2013 containing molecules market showed growth at 5.3 per cent whereas the non NLEM market grew at 5.1 % resulting in an overall growth of 5.1 % for the month of October’19.
Among the top brands, Mixtard has maintained the top position for the month of Oct’19. While Lantus has gained a position and moved to second position, while Glycomet-GP has slipped to third position.
Janumet has moved up to fourth position by replacing Galvus Met as fifth. Duphaston gained second position and climbed to eight position.
Few major brands who have dropped in ranks Phensedyl Cough Linctus (-3), Istamet (-6), Volini (-3), Zincovit (-4), Shelcal (-3).
From therapy (Super Group) perspective, 14 of the 20 therapies are reflecting a growth of average 5%. Highest among that being cardiac (7.9%), followed by hormones (6.5%), antidiabetic (6.4%) & neuro/CNS (6.1%)
Vitamins and minerals (2.3%), gynaecology (2.9%), anti-neoplastic (3.4%) & derma (3.6%) are showing lower growths, while urology, blood related and sex stimulants are showing 10% plus growth
From the regional perspective, 14 of the regions are above the IPM growth of 5.1% and 17 regions below the IPM.
As of MAT October, 19 patented and in-licenced brands contribute to 4.46% of IPM and contributes to 8.7% of the incremental gains in the IPM and growing at 17.9%.
Glimepiride+metformin market (Rs.2,390 crore), consolidated Rs.235 crore and reflecting a growth of 11% on MAT and 6.5% for the month. Amoxycillin+clavulanic acid market (Rs.2,201 crore) consolidated Rs.227 crore at a growth of 12%. Paracetamol market (Rs.1,129 crore) has consolidated Rs.163 crore and a growth of 17 per cent.
Itraconazole (Rs.935 crore) consolidated 107 crore with a growth of 13%. Montelukast+levocetirizine (Rs.812 crore) added 57% with a growth of 8%. The luliconazole market is worth Rs.434 crore is exhibiting a growth of 15 per cent.
Voglibose+metformin+glimepiride (Rs.796 crore) added 140 crore with a growth of 21%. Telmisartan (Rs.768 crore)growing at 18%, added Rs.116 crore. montelukast+levocetrizine (Rs.808 crore) is exhibiting growth of 12%
Domperidone+Esomeprazole and Domperidone+omeprazole that are growing at 21% and 13% respectively, pantoprazole at 9% and rabeprazole at 5 per cent. The vildagliptin market valued at Rs.997 crore has exhibited degrowth (-14%) for the month.
Gliptins market (3611 crore) continues to grow double digit in combinations, while monotherapy market stagnant/degrowing, sitagliptin (-0.32%), vildagliptin (1.78%), saxagliptin (-5%).
Comments
Post a Comment